Health
15 December 2023, 9:42 am 1 minute
Reuters exclusively reported that U.S. drug regulators in September found quality control lapses at Moderna’s (MRNA.O) main factory including with equipment used to manufacture drug substance for its COVID-19 vaccine.
Market Impact
Moderna in September said it was in talks with its partners that fill vials and syringes with its COVID vaccine globally to downsize production and bring more manufacturing in-house as demand has waned. The vaccine maker said it expects additional capacity from its new mRNA manufacturing facilities in the UK, Canada and Australia when completed in 2025.
Article Tags
Topics of Interest: Health
Type: Reuters Best
Sectors: Government & Public ServicesPharmaceuticals & Healthcare
Regions: Americas
Countries: United States
Win Types: Exclusivity
Story Types: Exclusive / Scoop
Media Types: Text
Customer Impact: Significant National Story
